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Abstract  
There is an increasing need of human organs for transplantation, of alternatives to animal 
experimentation, and of better in vitro tissue models for drug testing. All these needs create unique 
opportunities for the development of novel and powerful tissue engineering methods, among which the 
3D bioprinting is one of the most promising. However, after decades of incubation, ingenuous efforts, 
early success and much anticipation, biomaterial-dependent 3D bioprinting, although shows steady 
progress, is slow to deliver the expected clinical results. For this reason, alternative ‘scaffold-free’ 3D 
bioprinting methods are developing in parallel at an accelerated pace. In this opinion paper we discuss 
comparatively the two approaches, with specific examples drawn from the cardiovascular field. Moving 
the emphasis away from competition, we show that the two platforms have similar goals but evolve in 
complementary technological niches. We conclude that the biomaterial-dependent bioprinting is better 
suited for tasks requiring faster, larger, anatomically-true, cell-homogenous and matrix-rich constructs, 
while the scaffold-free biofabrication is more adequate for cell-heterogeneous, matrix-poor, complex and 
smaller constructs, but requiring longer preparation time.  
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Highlights  
• Research in bioprinting for cardiovascular applications is very dynamic and diverse. 
• This activity is classified as biomaterial-dependent and -independent (‘scaffold-free’) bioprinting.  
• Both are well represented in bioprinting of cardiac patches, but scaffold-free methods are more 
advanced in producing pre-clinical vascular grafts.  
• Biomaterial-based bioprinting is likely to become successful for larger, faster and less 
complicated tasks.  
• Scaffold-free variant might be preferred for smaller, more compact, cell-heterogeneous 
constructs.  
 
 
Abbreviations: 3DBP: 3D bioprinting; EC: endothelial cells; ECM: extracellular matrix; FB: fibroblasts; 
GelMA: metacrylate gelatin; HUVEC: human umbilical vein endothelial cells; IC: interstitial cells; MSC: 
mesenchymal stem cells; SMC: smooth muscle cells. 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
Introduction  
Medicine is facing new challenges in a world with an increasingly aged world population. Among 
them is the massive request of more tissues and organs for transplantation, although fewer than one-third 
of these patients eventually will receive one [1]. Also, due to their limited efficacy, more robust, possibly 
radical alternatives to current cell therapy-based methods to treat chronic diseases are needed. Another 
opportunity for tissue engineering is to replace, or possibly eliminate animal experimentation. This is 
desirable not only from a bio-ethical standpoint, but also in response to the practical issues derived from 
species-specific differences in cell function and tissue organization. In addition, more realistic 3D tissue 
models are increasingly required for toxicological testing and for drug discovery. In all circumstances, 
tissue engineering is taking a more central position in the emerging bio-medical toolkit [2].  
Among the tissue engineering methods, 3D bioprinting (3DBP) holds the promise to become a 
major revolution in biofabrication of tissues and organs [3]. This technology might also have an 
excellent opportunity in the context of deep space exploration: in long-term missions, with very limited 
resources, the only solution for urgent medical problems could be the on-demand 3D printing of both 
medical instruments [4] and the required tissues from a patient’s own cells [5].  
As a form of additive biomanufacturing, 3DBP has been riding so far on the wave of 3D printing. 
In other words, bioprinting became mainly the biological version of 3D printing [6]. However, the 
biomaterials deployed in a layer-wise manner to create the 3D construct, also named ‘bioinks’ (or 
‘scaffolds’ because of their supporting role), had to coincidently fulfill these often contradictory 
conditions: i) be printable; ii) protect incorporated cells during bioprinting; iii) sustain their growth and 
differentiation afterwards; iv) be biocompatible with the recipient organism [7].  
At the interface between scaffold-dependent and scaffold-free bioprinting lies the use of a new 
generation of ‘bioinks’ prepared exclusively from natural materials, such as collagen, fibrin or organ-
specific extracellular matrices[8]. Although still experiencing some of the same limitations of their 
deployment methods as their synthetic correspondents, the latter option is by far more promising in terms 
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of cell support and biocompatibility. But all these difficulties would be absent if the cellular assembling 
could be performed with cells capable to produce their own extracellular matrix (ECM), i.e., using 
biomaterial (‘scaffold’)-free methods.  
Terminological issues. One of the consequences of the field’s rapid expansion, with contribution 
of many research groups with expertise blended from different disciplines, is the inhomogeneous (and 
often confusing) terminology [3]. For example, bioprinting is the name given to: i) layer-by-layer 
deposition of cells dispersed in a biomaterial; ii) biomaterial-dependent assembling of cellular aggregates; 
iii) formation of cell aggregates (spheroids or larger constructs) by magnetic pull down, or even by 
centrifugation; iv) biomaterial-independent 3D assembling of cell cords and spheroids. Correspondingly, 
as the instrument facilitating the act of ‘bioprinting’, a ‘bioprinter’ may have different meanings. 
Moreover, for some groups the notion of ‘bioink’ represents only the embedding biomaterial used for 
bioprinting, while for others it includes the living entities used for 3D assembling [9]. Also, those 
procedures where biomaterials are removed shortly after assembling of pre-formed cellular aggregates as 
building blocks were also called ‘scaffold-free’ [10].  
 
Comparative examples of 3DBP for cardiovascular applications.  
Commensurate with the exceptional momentum for 3DBP, high-quality reviews of this rapidly 
evolving field are published almost daily, including many dedicated to cardiovascular applications (e.g. 
[7,11,12]) . In what it follows, we will comparatively discuss some recent publications focusing on the 
cardiovascular field, to help the readers evaluate the strengths and limitations of scaffold-dependent and 
scaffold-free approaches (see Table 1 for a summary [13]).  
 
1. Microvessels  
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One of the major roadblocks on the way towards engineering functional tissue constructs is the 
difficulty to provide them with the needed blood perfusion. A large effort is being conducted in almost 
every branch of tissue engineering to achieve this goal [14].  
Scaffold-dependent bioprinting. In two successive studies, one of the expert groups frontally 
addressed the problem of micro-vascularization of cell heterogeneous constructs. Illustrating the scale of 
the problem, in one study they used four bioinks [15,16], all being extrusion-applied as cylindrical 
threads, and further embedded in a metacrylate gelatin (GelMA) hydrogel base. Then a sacrificial 
Pluronic F127 ink was removed, producing empty channels subsequently seeded with human umbilical 
vein endothelial cells (HUVEC), which formed a monolayer during 9 days of culturing. However, these 
vascular tubes were not perfusable, thus limiting the thickness of bio-fabricated constructs to 1–2 mm and 
their survival to less than two weeks of culturing [15].  
The same group later bioprinted thicker constructs, perfused for more than 6 weeks, and showing 
osteogenic differentiation of mesenchymal stem cells (MSC) coupled to oxygen diffusion from the 
pseudo-vascular supply [16]. To this end the authors first bioprinted cell-laden bioinks composed of 
GelMA and fibrinogen, together with a fugitive bioink (Pluronic F127, thrombin and transglutaminase) 
applied on silicone perfusion chips on a glass substrate. Then the Pluronic-containing, temperature-
sensitive ink was removed, leaving behind a network of empty channels, which this time could be both 
endothelialized and perfused [16].  
Scaffold-free bioprinting. A simpler and more natural approach was used to incorporate EC 
during assembling of spheroids, as the basic mechanism of scaffold-free biofabrication [17]. For 
example, such spheroids made from human cardiomyocytes (CM), FBs and EC were prepared and 
assembled in a beating, single-spheroid layer, by flotation [18]. When this was applied as a cardiac patch 
on the surface of the heart in living immunodeficient rats, the construct had not only survived, but after 
retrieval it was found that blood perfused abundantly the spontaneously-organized capillaries 
anastomosed to recipient’s microvasculature [18].  
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As a materialization of the biomaterials-free tissue engineering approach, by facilitating the 
larger-scale fusion and maturation of spheroids in meaningful tissue constructs, is the use of a set of 
micro-needles (‘Kenzan’ in Japanese) as temporary supports [13,19]. This method was implemented in 
the Regenova ‘Bio-3D Printer’. Several such instruments are operational in Japan, and a few more in US. 
Various cell constructs have been printed on the Regenova robot, of which a small diameter vascular graft 
is best known [20], but also tracheal [21] and uretral [22] tubes, as well as liver, nerve and other tissues 
(http://www.cyfusebio.com/en/regenova.html). Work in progress in several labs (e.g., Novel Stem Cell 
Therapy for Heart Failure Using 3D Printed Cardiac Tissue, by Ong et al., Circulation 2016;134:A18056) 
indicate that microvascularization based on this principle is being used for Kenzan bioprinting of cardiac 
patches.  
Comparison. In the case of the material-based 3D constructs we see the direct, potentially 
anatomically correct (although this still has to be demonstrated) channel formation, followed by 
endothelial colonization, and possibly by perfusion. However, such soft biomaterial-dependent constructs 
could not be tested in vivo yet, while the prospect to eliminate all the supportive materials in the 
constructs is still remote (Fig. 1A1, Design flexibility vs. Architecture). In the scaffold-free method the 
endothelial cells (EC) are directly incorporated in pre-formed cell spheroids, with subsequent self-
organization in microvascular networks which spontaneously connect (anastomose) with the recipient’s 
capillaries. However, their direct connection to larger vessels is still to be demonstrated (Fig. 1A2, 
Anastomosis vs. Connectivity). Thus, at face value, the latter method seems to be closer to pre-clinical 
testing. With some improvements, this approach could become a viable solution to the micro-
vascularization needs of scaffold-free tissue engineered constructs in general. In addition, lymphatic cells 
and even neural cells could be introduced in a similar way.  
2. Large vessels 
Scaffold-dependent bioprinting. Tissue engineering of vascular grafts was traditionally an active 
area of research, with notable recent progress in use of natural (such as fibrin [23]) or artificial (e.g., 
fibrillar polycaprolactone [24]) biomaterials, or of decellularized vessels [25]. However, we could not 
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find convincing demonstrations of free-standing scaffold-dependent bioprinted vascular grafts ready to be 
tested in vivo. The reason is simple: the mechanical properties of hydrogels which are needed for 
bioprinting may not be compatible with this application, even with a post-printing hardening step, but the 
search for this ‘holy grail’ continues nevertheless. A recent example of cell incorporation in layered 
biomaterial tubes is the work by Wilkers et al. [26]. Multilayered cylindrical constructs were obtained 
by deposition of biomaterials on rotating mandrels of different diameters, made of fugitive (removable) 
alginate. The authors could print tubes with lumens in the 0.5-6 mm diameter range, with layers of 1-400 
µm from GelMA, alginate and chitosan. Only HUVEC were added to these layers (e.g., to a 20–30 µm 
intima), which demonstrated good viability and proliferation. No additional assessments besides 
microcopy were reported, since the authors noted the extreme fragility of the construct (Fig. 1B1, 
Precision vs. Resistance). In addition, they acknowledged the limited range of polymerization parameters 
explored, constrained by requirements to maintain cell viability.  
Scaffold-free bioprinting. In the scaffold-free camp there is more convincing progress: a generic 
vascular-like tube obtained by the Kenzan method from human smooth muscle cells (SMC), fibroblasts 
and EC, with about 1.5 mm in thickness and 5 cm in length [20]. This tube, completely made of living 
cells, could be grafted in abdominal aorta in rats, while remaining patent for five days. Although having a 
burst pressure ten times more than a human vessel of same caliber, this vascular graft still eventually 
failed, likely because of slow expansion and remodeling, due to the lack of organized elastic elements 
[20](Fig. 1B2, Cell composition vs. Biomechanics). Previously reported small-diameter vascular tubes 
[27] or torroids [28] were obtained by ‘hybrid’ bioprinting (i.e. using fugitive alginate molds).  
Another biomaterial-free approach exploits the versatility of magnetic force, deployed via 
magnetic nanoparticles. Since the internalization of commonly used magnetite (iron oxide) has some 
toxicity on cells, different alternative strategies have been proposed. By separating the cell-rich and 
magnetite-rich domains within cellular spheroids (creating the so-called ’Janus’ spheroids [29]), 
spheroids with lesser magnetite incorporation were used to assemble rings reminiscent of vascular tubes 
[30]. Alternatively, the use of the more biological-compatible reagent magnetoferritin, which has fewer 
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adverse effects on cells for up to 1 week, has been suggested by the same group [31]. Cellular spheroids 
labeled with this reagent were magnetically brought and maintained in contact and fused into tissue rings 
[31].  
Comparison. Scaffold-free methods seem to be again more advanced in their ability to produce 
meaningful, testable vascular grafts of surgical interest. Although these are also still not enough resistant 
to blood pressure, they are readily amendable to improvements, for example by additional extracellular 
matrix-targeted engineering [30], or by hybrid methods, such as incorporating additional - albeit 
temporary - biodegradable supporting scaffolds.  
 
3. Cardiac valves 
Heart valves are anatomically complex and cell-heterogeneous layered tissues prone to 
substantial damage [32]. Cardiac valves are comprised of three cellular layers: two layers of EC on the 
surface of valvular leaflet, sandwiching a layer of interstitial cells (IC) within a complex ECM. Valvular 
EC convey signals from bloodstream, mediate their lipid uptake and the anti-inflammatory and anti-
thrombotic responses, and maintain the IC quiescent. IC have a phenotype intermediate between 
fibroblast and SMC, and are mainly responsible with the secretion of a structural ECM. Interaction 
between these cell types is also instrumental for valve function. Valvular EC injury induces inflammation, 
thrombosis, and lipid and/or calcium accumulation, coincident with IC activation, increased smooth 
muscle-type actin expression, and ECM remodeling. These factors trigger in IC an osteoblastic 
phenotype, leading to valvular calcification and stenosis [32].  
In spite of the remarkable progress in surgical replacement with either inorganic or animal-
derived prostheses, there is still a large need for improvement in heart valve tissue engineering. 3DBP 
could in principle address the limitations of current valve replacement options [12]. Also desirable would 
be valvular image-driven constructs with a personalized geometry, or in pediatric patients, valves capable 
to grow and remodel. However, despite significant progress in other areas of valvular tissue engineering 
[33,34] to our knowledge no functional testing has been reported of any of the bioprinted valves.  
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Scaffold-dependent bioprinting. An anatomically relevant tri-leaflet valve model was developed 
by extrusion bioprinting, using rigid (root) and soft (leaflets) hydrogels [35,36]. Aortic root SMC 
embedded into the root and aortic valve IC in the leaflet portions of the printed valve remained viable for 
7 days in culture, and expressed α-smooth muscle actin and vimentin, respectively. IC deposited their 
own collagen- and glycosaminoglycan-rich ECM. Although EC were not included in this work, it 
nevertheless demonstrated that complex and cell-heterogeneous cardiac valves could be bioprinted. The 
main problem remains the biomaterial, because cell survival was suboptimal and needed improvement 
[37], while the anticipated replacement with native matrix apparently did not progress too far, sine no 
biomechanical testing of these constructs has been reported yet (Fig. 1C1, Geometry vs. Material).  
Scaffold-free bioprinting. Layered co-cultures of aortic valve cells (EC and IC) were prepared and 
cultured using magnetic levitation [38]. This method has been employed previously to create a variety of 
other 3D culture models (vascular smooth muscle [39], pulmonary [40], tumoral [41], and adipose [42] 
stem cells). To this end, the cells were first incubated with a proprietary (commercial) reagent consisting 
of poly-L-lysine, magnetite and gold nanoparticles, and formed a gel that attached reversibly by 
electrostatic interactions with the cell surface, making it less toxic than other magnetic particle reagents. 
After three days in culture, the cells maintained their phenotype, as shown by staining for the EC marker 
CD31, endothelial nitric oxide synthase, von Willebrand factor and prolyl-4-hydroxylase, and for smooth 
muscle actin in the IC. The increase in endothelial nitric oxide synthase and von Willebrand factor 
expression by EC in the construct, as compared to normal cultures, suggested that they might be less 
thrombogenic in the presence of IC cells. Quiescence of the IC as compared to 2D cultures was 
demonstrated by reduced expression of the collagen I, lysyl oxidase and smooth muscle actin genes. The 
ECM proteins collagen type I, laminin and fibronectin were detected within the construct by 
immunostaining. A major limitation of this study was the simple, two-layered geometry of the construct, 
which again did not permit integration in an anatomically meaningful construct and biomechanical testing 
(Fig. 1C2, Cell organization vs. Integration).  
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Interestingly, although vascular rather than valvular cells have been used, the tri-laminar structure 
of a cardiac valve leaflet was produced using the ‘Janus’ magnetic cell spheroids [30]. Given the overall 
potential of spheroids-based tissue engineering, these early attempts are definitely worth continuing with 
valvular cells as well.  
Comparison. Apparently, both biomaterial-dependent and scaffold-free bioprinting of artificial 
valves lag behind other scaffold-based versions of valvular tissue engineering. This is not surprising, 
given the need for a printable material similar to valve’s heterogeneous ECM, which is critical for its 
structure and biomechanics. 
 
4. Myocardial tissue 
 
At cellular level, heart’s basic units (myofibers) are organized in rather parallel fashion, an 
alignment that combined with the contractile synchronization of myocytes, promotes their electric 
activity. Conceptually, this structure could be relatively easily implemented by bioprinting.  
Scaffold-dependent bioprinting. Several forms of cardiac patches were prepared by bioprinting so 
far. For example, Gaebel et al. used laser-assisted bioprinting to seed HUVEC and human MSC in a 
pattern used as cardiac patch [43]. Similarly, human fetal CM progenitors were bioprinted in an alginate 
base to fabricate a cardiogenic patch with defined pore size and with satisfactory viability [44]. However, 
neither of these attempts achieved the cell density required for a functional myocardial analog [45].  
A substantial advance in this regard was recently reported, which relies on a high resolution 
photochemistry-based 3D printing method (two-photon photolithography) to generate a pattern in the 
scaffold, extracted directly from microscopic images of the architecture of native myocardial ECM, then 
seeded with human induced pluripotent stem-derived cardiac cells. This cardiac patch promoted high 
levels of cell engraftment, and improved cardiac function, vascularity, and cell proliferation in the 
adjacent recipient tissue, thus reducing infarct size in a murine model of myocardial infarction [46]. 
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However, scaling-up this construct to patch a human infarced heart is the next big challenge (Fig. 1D1, 
Matrix structure vs. Scaling).  
Scaffold-free bioprinting. Several research groups are engaged in the use of Kenzan method to 
produce a scaffold-free cardiac patch (e.g. Ong et al., Circulation 2016;134:A18056). In fact, its building 
blocks, i.e., spheroids prepared from cardiomyocytes, fibroblasts (FB) and EC, have been already 
assembled in a beating, viable cardiac patch, and implanted in rats. This patch showed excellent cell 
survival and perfusion, consecutive to anastomosis with the recipient capillaries of the built-in 
microvascular primordia self-assembled during the maturation phase of the construct. However, as 
described before, this construct was obtained by simple flotation of one layer of spheroids on the surface 
of culture dish, rather than using the bioprinter. For this reason it had a thickness (given by the diameter 
of the spheroids) of only about 0.5 mm, a limitation that several teams are currently aiming to surpass by 
actual Kenzan bioprinting in multiple spheroid layers.  
In another significant development, cell spheroids were assembled within a microfluidic device 
by direct inter-cell ‘click’ ligation, a liposome-based technology which displays bio-orthogonal functional 
groups on cell membranes [47]. This method could be one day used to create larger cardiac patches, 
because the same group already applied it to the engineering of cell-to-cell contacts between liver cells 
[48] and amongst all cardiac cell types [45]. When compared with 2D co-culture monolayers, these 3D 
cardiac tissue ‘chips’ showed increased cardiac markers, electromechanical coupling, beating rates and 
reduced toxicity of tested drugs [45](Fig. 1D2, Cell density vs Size).  
Comparison. Apparently, incorporation of cardiomyocytes into biomaterials for creation of 
cardiac patches with pre-clinical relevance is the most advanced cardiovascular application of both 
scaffold-dependent and independent bioprinting to date. However, scaling up of the method, 
biocompatibility of the materials, as well as micro-vascularization of the construct still makes uncertain 
the ultimate clinical fate of this otherwise promising scaffold-dependent approach. At the same time, 
scaffold-free methods also take speed, with use of the microneedle technology and other versions of direct 
engineering of the cell-to-cell interactions.  
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Conclusion 
In a domain as complex as cardiovascular tissue engineering, it is hard to predict which of these 
emerging technologies will succeed, and/or will become dominant. Most likely, both will soon occupy 
their best fitting application niches. By corroborating developments from other branches of bioprinting 
discussed elsewhere [13], we anticipate that (pending transcending a number of remaining roadblocks), 
scaffold-dependent bioprinting may be taking the lead for constructs which are larger, more cell-
homogenous, high-matrix tissues, such as the musculoskeletal system and myocardial tissue (and possibly 
cardiac valves).  
At the same time, the creation of smaller, cell-heterogeneous, low-matrix tissues, e.g. micro-
vascularization of a variety of tissues such as glands and sensory organs, will probably better be served by 
scaffold-free biofabrication approaches. Not unlikely, these versions of biofabrication will share the same 
application landscape depending on the required speed to completion and complexity. For example, if a 
large skin surface needs to be made fast to cover a burned dorsal area, the scaffold-dependent bioprinting 
may better help. However, if the time and conditions permit, skin patches containing not only the 
protective dermal layers in an appropriate ECM embedding, but also glands, hair, capillaries and nerves 
could someday be better made using the scaffold-free approach.  
In summary, neither one of the two modes of performing bioprinting (biomaterial-dependent or 
‘scaffold-free’) has convincingly shown pre-clinical examples of success yet. However, as discussed here, 
the less known scaffold-free methods (specifically the Kenzan and magnetic nanobead-assisted) methods 
show promising advances to complement, and in some areas to surpass, the fast-pacing scaffold-
dependent bioprinting. 
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the Indiana University-Purdue University at Indianapolis.   
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Figure legend:  
Figure 1. Graphical comparison of biomaterial-dependent and -independent cardiovascular 
constructs. Selected examples illustrate the major benefits (green highlight) and limitations (red 
highlight), in our opinion, of the respective methods. A. Microvasculature: from 
https://en.wikipedia.org/wiki/Capillary#/media/File:Capillary_system_CERT.jpg; A1: Kolesky et al. [15]; 
A2: Noguchi et al. [18] B. Large vessels: from Blausen.com. "Blausen gallery 2014". Wikiversity 
Journal of Medicine. DOI:10.15347/wjm/2014.010; B1: Wilkers et al. [26]; B2. Itoh et al. [20], C. 
Cardiac valves: from http://cnx.org/content/col11496/1.6/; C1: Cai/Duan et al. [36], C2: Mattix et al. 
[29], D. Myocardial muscle: from Patrick J. Lynch, medical illustrator; C. Carl Jaffe, MD, cardiologist. 
http://creativecommons.org/licenses/by/2.5/; D1: Gao et al. [46]; D2: Rogozhnikov et al. [45] 
(Reproduced with permission). See explanations in text.  
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
15 
 
  
BIOMATERIAL
-DEPENDENT  
BIOMATERIAL-
FREE  
 Attributes Comments  Attributes  Comments 
OBJECT 
CONFIGURAT
ION 
Direct image input 
via CAD Similar to 3D printing Approximate 
Larger ‘voxel’ size, limited 
resolution  
STRUCTURAL  
COHESION 
(‘glue’) 
Obtained by non-
universal, 
sometimes 
proprietary and/or 
expensive bio-inks  
New biological bio-
inks emerging (e.g. 
collagen or fibrin 
based) 
Cells produce their 
own matrix; 
constructs are 
dependent on cell 
type and quality 
Matrix deposition can be 
unpredictable or insufficient 
BIOMECHANI
CS 
Hydrogels are 
essentially soft; 
hardening can be 
cell-damaging  
‘Hybrid’ bioprinting 
as alternative: 
incorporation of a 
second (fibrillar) 
biomaterial 
Construct 
biomechanics less 
predictable and 
controllable  
Hybrid versions are also 
likely to be developed 
EFFICIENCY 
Substantial cell 
death, for a variety 
of method-specific 
reasons  
Milder methods are 
being tested (e.g. 
laser-assisted 
bioprinting) 
Less or no cell 
damage 
Cell-type 
dependent  
By using large spheroids, 
speed can become 
comparable or even higher 
than laser-assisted 
bioprinting 
CELLULAR  
CROSS-TALK 
Material-limited 
inter-cellular 
communication 
(‘encapsulation’)  
Not a problem for 
matrix-rich tissues 
such as bone, 
cartilage 
Direct cellular 
interactions 
Optional addition of 
hydrogels into or between 
spheroids still possible 
TISSUE  
STRUCTURE 
Simplistic cellular 
architecture   
Biomaterial 
dissolution allows 
more spontaneous cell 
rearrangements 
Follows 
developmental 
principles  
Incorporation of endothelial 
cells in spheroids may 
promote micro-
vascularization 
BIO-
COMPATIBILI
TY 
Cytotoxicity 
possible, foreign-
body reactions 
likely 
Less serious if 
biological bio-inks 
are used 
Patient-specific 
cells: MSC, iPSC 
Possibly fully autologous 
constructs 
COMMON 
TECHNICAL 
PROBLEMS 
Nozzle clogging 
Limited to ink-jet and 
micro-extrusion 
methods 
Time of pre-
printing 
preparations 
Post-printing maturation 
time comparable between 
the two approaches 
SCALABILITY Excellent 
Good for large, cell-
homogenous,  
matrix-rich tissues       
More limited 
Recommended for small, 
cell-heterogeneous, matrix-
poor tissues 
 
Table 1. Comparative features of biomaterial-dependent and independent bioprinting methods. 
(reproduced with permission from Moldovan et al., 201613).  
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